Factors associated with the effectiveness of immersive virtual therapy in alleviating depressive symptoms during sub-acute post-stroke rehabilitation: a gender comparison.
Depressive symptoms
Mental health
Neurorehabilitation
Stroke
Virtual reality
Journal
BMC sports science, medicine & rehabilitation
ISSN: 2052-1847
Titre abrégé: BMC Sports Sci Med Rehabil
Pays: England
ID NLM: 101605016
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
15
05
2023
accepted:
25
09
2023
medline:
21
10
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
The large-scale digitalization of healthcare has induced shifts in patient preferences, prompting the introduction of therapies utilizing novel technologies. In this context, the targeted application of these interventions is deemed as crucial as assessing their overall effectiveness. The aim of this study was to characterize the patient profile who benefited most from immersive virtual reality (VR) therapy. Based on the results from the previous randomized controlled trial study, we employed an exploratory study design to determine the factors associated with the most significant mental health improvement. A secondary analysis was conducted on a sample of 83 participants, with further analysis of participants with elevated depression symptoms, as indicated by a score of > 10 on the 30-item Geriatric Depression Scale (GDS-30). Both groups participated in a similar post-stroke rehabilitation program; however, the experimental group also received additional VR therapy through an immersive VR garden intervention. The GDS-30 was used to assess mood and depressive symptoms, and sociodemographic, cognitive status as well as stroke-related variables were considered as potential factors. In both the experimental (mean change 5.3) and control groups (mean change 2.8), interventions significantly reduced depressive symptoms, with a more pronounced difference in the experimental group (p < 0.05). When examining gender differences, women exhibited greater improvement in the GDS, with mean between-group differences of 5.0 for the total sample and 6.0 for those with elevated depressive symptoms. Sociodemographic factors, cognitive status, and time from stroke were not found to be factors that alter the effectiveness of VR therapy. While VR therapy as an adjunctive treatment for post-stroke rehabilitation seems especially effective for women with elevated depressive symptoms, the results should be interpreted with caution due to the study's small experimental group size. Traditional methods showed reduced effectiveness in women compared to men; thus, developing technologically advanced and gender-specific approaches can lead to more tailored therapy. NCT03830372 (February 5, 2019).
Sections du résumé
BACKGROUND
BACKGROUND
The large-scale digitalization of healthcare has induced shifts in patient preferences, prompting the introduction of therapies utilizing novel technologies. In this context, the targeted application of these interventions is deemed as crucial as assessing their overall effectiveness. The aim of this study was to characterize the patient profile who benefited most from immersive virtual reality (VR) therapy.
METHODS
METHODS
Based on the results from the previous randomized controlled trial study, we employed an exploratory study design to determine the factors associated with the most significant mental health improvement. A secondary analysis was conducted on a sample of 83 participants, with further analysis of participants with elevated depression symptoms, as indicated by a score of > 10 on the 30-item Geriatric Depression Scale (GDS-30). Both groups participated in a similar post-stroke rehabilitation program; however, the experimental group also received additional VR therapy through an immersive VR garden intervention. The GDS-30 was used to assess mood and depressive symptoms, and sociodemographic, cognitive status as well as stroke-related variables were considered as potential factors.
RESULTS
RESULTS
In both the experimental (mean change 5.3) and control groups (mean change 2.8), interventions significantly reduced depressive symptoms, with a more pronounced difference in the experimental group (p < 0.05). When examining gender differences, women exhibited greater improvement in the GDS, with mean between-group differences of 5.0 for the total sample and 6.0 for those with elevated depressive symptoms. Sociodemographic factors, cognitive status, and time from stroke were not found to be factors that alter the effectiveness of VR therapy.
CONCLUSIONS
CONCLUSIONS
While VR therapy as an adjunctive treatment for post-stroke rehabilitation seems especially effective for women with elevated depressive symptoms, the results should be interpreted with caution due to the study's small experimental group size. Traditional methods showed reduced effectiveness in women compared to men; thus, developing technologically advanced and gender-specific approaches can lead to more tailored therapy.
TRIAL REGISTRATION
BACKGROUND
NCT03830372 (February 5, 2019).
Identifiants
pubmed: 37864252
doi: 10.1186/s13102-023-00742-z
pii: 10.1186/s13102-023-00742-z
pmc: PMC10588095
doi:
Banques de données
ClinicalTrials.gov
['NCT03830372']
Types de publication
Journal Article
Langues
eng
Pagination
137Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Top Stroke Rehabil. 2021 Sep;28(6):422-431
pubmed: 33078689
J Clin Med. 2021 May 01;10(9):
pubmed: 34062721
Work. 2018;61(4):523-535
pubmed: 30475778
Ther Adv Neurol Disord. 2018 Jul 30;11:1756286418789854
pubmed: 30083232
Memory. 2007 Feb;15(2):192-204
pubmed: 17534112
Virtual Real. 2023 May 7;:1-9
pubmed: 37360811
J Rehabil Med. 2020 Nov 13;52(11):jrm00120
pubmed: 32965505
Med Sci Monit. 2022 Feb 16;28:e933367
pubmed: 35169111
Int J Environ Res Public Health. 2022 Mar 29;19(7):
pubmed: 35409756
Arch Gen Psychiatry. 2010 Mar;67(3):220-9
pubmed: 20194822
J Behav Med. 2016 Feb;39(1):55-64
pubmed: 26245159
Arch Gerontol Geriatr. 2020 Mar - Apr;87:104002
pubmed: 31881393
Arch Phys Med Rehabil. 2017 Apr;98(4):687-694
pubmed: 27847195
Gen Hosp Psychiatry. 2015 May-Jun;37(3):245-50
pubmed: 25817322
Proc Annu Symp Comput Appl Med Care. 1991;:938-40
pubmed: 1807758
Biomed Res Int. 2019 Jun 18;2019:7595639
pubmed: 31317037
Cerebrovasc Dis. 2016;41(1-2):19-26
pubmed: 26580841
Int J Public Health. 2017 Jul;62(6):647-656
pubmed: 28337512
Dtsch Arztebl Int. 2009 Apr;106(15):262-8
pubmed: 19547627
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S454-66
pubmed: 22588766
Front Neurol. 2021 Jan 14;11:618330
pubmed: 33519699
Front Aging Neurosci. 2021 Dec 13;13:766525
pubmed: 34966267
Front Neuroendocrinol. 2022 Jul;66:101010
pubmed: 35716803
Clin Interv Aging. 2022 Nov 23;17:1673-1685
pubmed: 36447623
J Rehabil Med. 2020 Nov 19;52(11):jrm00121
pubmed: 33073855
J Am Med Dir Assoc. 2021 May;22(5):995-1002
pubmed: 33812843
Jt Comm J Qual Improv. 1998 Jul;24(7):347-60
pubmed: 9689568
Healthcare (Basel). 2022 Apr 16;10(4):
pubmed: 35455922
Int J Soc Psychiatry. 2018 Feb;64(1):92-103
pubmed: 29212385
Acta Neurol Scand. 2008 Feb;117(2):133-40
pubmed: 18184349
Med Klin. 1950 Aug 4;45(31):945-9; contd
pubmed: 15438602
Circulation. 2014 Jan 21;129(3):e28-e292
pubmed: 24352519
Sensors (Basel). 2023 Feb 03;23(3):
pubmed: 36772757
Brain. 2022 Apr 18;145(2):457-475
pubmed: 34918041
Prog Neurobiol. 2019 May;176:86-102
pubmed: 30721749
PLoS One. 2018 Jul 16;13(7):e0200525
pubmed: 30011299
Cochrane Database Syst Rev. 2017 Nov 20;11:CD008349
pubmed: 29156493
Prev Med Rep. 2016 Nov 14;5:92-99
pubmed: 27981022
Stroke. 2010 Oct;41(10):2402-48
pubmed: 20813995
Lancet. 2014 Jan 18;383(9913):245-54
pubmed: 24449944
J Cereb Blood Flow Metab. 2018 Dec;38(12):2179-2191
pubmed: 30114967
Clin Geriatr Med. 1999 Nov;15(4):785-99
pubmed: 10499935
Biochim Biophys Acta. 2016 May;1862(5):915-25
pubmed: 26806700
J Phys Ther Sci. 2015 Jul;27(7):2057-60
pubmed: 26311925
NPJ Digit Med. 2023 Aug 24;6(1):159
pubmed: 37620411
Menopause Int. 2009 Jun;15(2):76-81
pubmed: 19465674
Neurol Sci. 2021 Mar;42(3):805-809
pubmed: 33433756
Am J Med Qual. 2002 Mar-Apr;17(2):47-55
pubmed: 11941994
Disabil Rehabil. 2016;38(1):30-5
pubmed: 25655394
Complement Ther Med. 2020 Aug;52:102480
pubmed: 32951730
Asian J Psychiatr. 2020 Feb;48:101863
pubmed: 31901586